Our study strongly suggest that IL-9 has the potential to mediate structural damage in inflammatory bone diseases such as RA by the enhancing the differentiation of osteoclasts, its bone resorptive capacity, and by modulating the expression of MMPs. Here, IL9 is linked to bone inflammation disease.